Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

186.06 +5.69 (+3.15%)
Official Closing Price Updated: 4:10 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbbVie

< Previous 1 2 3 4 5 6 7 8 Next >
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
MarketBeat Week in Review – 2/13 - 2/17
Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
AbbVie Has a Mixed Outlook After Mixed Earnings
AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold 
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. 
Via MarketBeat
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
4 High-Yield Dividend Kings For 2023
These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors. 
Via MarketBeat
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
From Immunome, Inc.
Via Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
MarketBeat: Week in Review 11/14 – 11/18
This week, investors digested negative news from the retail sector and the Fed and next week's abbreviated trading week won't bring much new news. 
Via MarketBeat
Topics Economy Workforce
Exposures Economy Interest Rates Layoff
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
MarketBeat: Week in Review 10/31-11/4
You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Exposures COVID-19
Why is AbbVie Stock Falling, but Still Good Long-Term?
Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
As Sales of Botox and Juvederm Begin to Stall, the Abbvie Stock Price Drops
AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm... 
Via PressReach
Topics Economy
Exposures Economy Interest Rates
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain 
Via MarketBeat
Topics Economy
Exposures Economy
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints New Board Member
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Should AbbVie Inc. Have a Place in Your Dividend Portfolio?
Does AbbVie Inc. fit well into your portfolio? We'll take a look at several factors before you decide whether investing in shares makes sense for your needs. 
Via MarketBeat
ABBVIE INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of AbbVie Inc. - ABBV
From Kahn Swick & Foti, LLC
Via Business Wire
NYSE:ABBV Long Term Shareholder Notice: Investigation of Potential Wrongdoing at AbbVie Inc.
San Diego, CA -- (SBWIRE) -- 08/10/2022 -- Certain directors of AbbVie Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
Are Medtronic And Intuitive Surgical Poised For Big Growth?
Health care is one of the better-performing sectors in 2022, with medical gear makers Medtronic and Intuitive Surgical outpacing the broader industry recently. 
Via MarketBeat
Topics ETFs
Exposures COVID-19
Two Appealing Biotech Stocks for Two Distinct investors
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
3 Pharma Stocks' Post-Earnings Price Moves
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market. 
Via MarketBeat
Topics ETFs Stocks
Exposures US Equities
MarketBeat: Week in Review 7/25 – 7/29
The markets are rallying as big tech earnings are lifting investors' spirits. Here are some of the stocks our analysts were looking at this week. 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy Interest Rates
Should You Buy AbbVie Ahead Of Earnings?
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment? 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.